Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia.
Tell us how you invest and we’ll show you why it’s our #1 pick
Tap here. – Revenue growth of 27.3% was primarily driven by a structural shift in customer demand toward AI-driven drug discovery (AIDD) and high-throughput protein expression. – Management attributes the record adjusted net profit growth of over 200% to improved business quality and operating leverage from long-term investments in automation and digital capacity. – The Life Science Group (LSG) achieved a 29.5% adjusted operating margin, marking a transition from an investment phase to a scale-and-profitability phase. – AI-driven demand is transforming the business model from one-off transactional projects to recurring, high-volume data generation partnerships with tech companies and AI-native biotechs. – Operational efficiency was enhanced by equipping approximately 60% of labs with AI-driven automated workstations, enabling industry-leading 4-day turnaround times for gene-to-protein validation. – The company is positioning itself as a critical infrastructure provider for the ‘AI for Science’ era, focusing on closing the loop between digital design and biological execution. Strategic Outlook and Guidance Assumptions – Full-year revenue growth guidance for the Life Science segment was raised to 25%-30%, reflecting strong visibility into AIDD-related order momentum. – AIDD orders are projected to double in the second half of 2026, with management expecting this hyper-growth trajectory to compound over the next several years. – The company expects to achieve positive EBITDA for the ProBio CDMO segment by 2027, supported by a 54% year-over-year increase in new orders. – CapEx for 2026 is projected at approximately USD 130 million, focused on doubling throughput capacity every quarter to meet surging AI-driven validation demand. – Management assumes that the premium margins for AIDD services…